# Cardiolink Science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardiolink-science

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.cardiolink.com.cn
- Latest round: Series D (Dec 30, 2021)
- Investors on record: 10

## About

Established in 2014 and based in Shenzhen, China, Cardiolink Science is a medical health company that focuses on research and development of tumor minimally invasive interventional delivery system. The company is headquartered in Shenzhen and has two subsidiaries in Beijing. The company has completed 4 rounds of funding as of 2021. The founder team has more than ten years of experience in the field of interventional devices. As of 2021, the company has obtained 7 Class III medical device registration certificates.

The company's main business is research, development, production and sales of medical devices in the field of tumor intervention. The company self developed products include peripheral & tumor interventional medical equipment, neurointerventional medical equipment, coronary interventional medical equipment and medical protective equipment. The peripheral & tumor interventional medical devices such as arteriovenous fistula balloon dilatation catheter and disposable interventional micro catheter. The coronary interventional products such as guided extension catheters and single-use dual-lumen microcatheters.

The company plan to use the series D funding to development of a new generation of embolic microspheres and other tumor interventional treatment product lines.

## Funding rounds

- Series D, Dec 30, 2021 — China International Capital Corporation, Astra Zeneca CICC Healthcare Venture Capital Fund
- Series C, Dec 31, 2020 — YuanBio Venture, GL Ventures
- Series B, Nov 17, 2019 — Shenzhen HTI, Efung Capital, Hangzhou Fuzhuo Venture Capital, SMECG Talent Equity Investment Fund Management
- Series B, Jun 1, 2019 — LYFE Capital
- Series A, Apr 28, 2016 — ZTE Venture Capital

## Investors

- ZTE Venture Capital (https://capitalatlas.ai/funds/zte-venture-capital) — Series A
- LYFE Capital — Series B
- Shenzhen HTI (https://capitalatlas.ai/funds/shenzhen-hti) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Hangzhou Fuzhuo Venture Capital (https://capitalatlas.ai/funds/hangzhou-fuzhuo-venture-capital) — Series B
- SMECG Talent Equity Investment Fund Management (https://capitalatlas.ai/funds/smecg-talent-equity-investment-fund-management) — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series C
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series D
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series D